MedTrace Logo

Escitalopram Treatment of Patients With Agitated Dementia

NCT00260624 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-02-24

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of escitalopram (Lexapro) using 10 or 20 mg daily in patients with Alzheimer's disease who are also experiencing agitation.

Conditions

Interventions

DRUG

Escitalopram (Lexapro)

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • University of Rochester

    lead OTHER

Principal Investigators

  • Adrian Leibovici MD · University of Rochester

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
61 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00260624 on ClinicalTrials.gov